AI platform for predicting lung cancer lymph node malignancy during ultrasound staging
Official title: The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer
Run by McMaster University · NCT06540196 · Data updated 2026-11-12
This study is testing a new AI tool to see if it can help doctors better determine if lymph nodes are cancerous in patients with non-small cell lung cancer during ultrasound procedures.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | McMaster University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Hamilton, Ontario) |
| Status | Recruiting |
| Started | January 10, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 30, 2026 |
| Trial ID | NCT06540196 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older diagnosed with suspected or confirmed NSCLC who have completed CT and PET scans and are referred for chest staging by EBUS-TBNA.
✕Probably not a fit
Patients with cN0 disease, peripheral tumors, or tumors smaller than 2 cm may not benefit from this study as they do not require chest staging.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates an artificial intelligence-powered platform called NodeAI, designed to enhance the accuracy of mediastinal lymph node staging in patients with non-small cell lung cancer (NSCLC) during endobronchial ultrasound (EBUS) procedures. The platform aims to provide real-time predictions regarding the malignancy of lymph nodes, addressing the current challenge of inaccurate staging results that can lead to misinformed treatment decisions. By utilizing advanced algorithms, NodeAI seeks to improve the diagnostic pathway for lung cancer and optimize treatment strategies for patients. The study will involve patients who have undergone CT and PET scans and are referred for chest staging by EBUS-TBNA.
Why it matters
Potential benefit: If successful, this platform could significantly improve the accuracy of lung cancer staging, leading to better-informed treatment decisions and potentially improved patient outcomes.
How similar studies have gone: While the use of AI in medical diagnostics is an emerging field, this specific approach to real-time prediction of lymph node malignancy during EBUS staging is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥ 18 years of age diagnosed with suspected or confirmed NSCLC based on CT and PET scans that are referred for chest staging by EBUS-TBNA * CT and PET scans completed Exclusion Criteria: * Patients with cN0 disease AND peripheral tumors AND tumors \< 2 cm in diameter (those do not require chest staging)
Where it's running
-
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Waël C. Hanna, MDCM, MBA, FRCSC
- Email: hannaw@mcmaster.ca
- Phone: (905) 522-1155
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC
In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.
-
Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer
This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.
-
3-D virtual resection to predict lung function after VATS anatomical lung surgery
The study will test whether a 3-D virtual resection from thin-slice CT scans can better predict lung function after VATS lobectomy or segmentectomy for people with non-small cell lung cancer.
-
Precise Exercise Regimen for Cancer Care: a small pilot in stage II/III NSCLC
This pilot tests the PERCC exercise program to see if it’s feasible for adults with stage II–III non-small cell lung cancer who are planned for neoadjuvant therapy and surgery.
-
PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer
This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.